Obstet Gynecol Sci.
2024 May;67(3):339-340. 10.5468/ogs.24074.
Progestogen in menopausal hormone therapy and breast cancer risk
- Affiliations
-
- 1Department of Obstetrics and Gynecology, Sanggye Paik Hospital, School of Medicine, Inje University, Seoul, Korea
- KMID: 2555518
- DOI: http://doi.org/10.5468/ogs.24074
Reference
-
References
1. Manson JE, Chlebowski RT, Stefanick ML, Aragaki AK, Rossouw JE, Prentice RL, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women’s Health Initiative randomized trials. JAMA. 2013; 310:1353–68.2. Yuk JS. Relationship between menopausal hormone therapy and breast cancer: a nationwide population-based cohort study. Int J Gynaecol Obstet. 2024. Mar. 12. [Epub]. https://doi.org/10.1002/ijgo.15461.3. Fournier A, Berrino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat. 2008; 107:103–11.4. Yuk JS, Kim T, Cho H, Gwak G. Breast cancer risk association with postmenopausal hormone therapy: Health Insurance Database in South Korea-based cohort study. Eur J Endocrinol. 2024; 190:1–11.
